Company case study
Ineos
Ineos is a chemical company that was formed as a spin-off of BP, focusing on producing various chemicals used in consumer products. It came up on My First Million in the episode "How to manufacture a billionaire childhood" (aired May 13, 2026). As told on the show: $40 billion in revenue, with a strategy to double EBITDA in five years.
At a glance
| Podcast | My First Million |
|---|---|
| Hosted by | Sam Parr and Shaan Puri |
| Episode | How to manufacture a billionaire childhood |
| Aired | May 13, 2026 |
| Revenue and traction | $40 billion in revenue, with a strategy to double EBITDA in five years. |
| Category | E-commerce |
Figures and claims are as told on the episode, summarized from the transcript. Check the date: they describe the company at the time it aired.
What the episode said
How to manufacture a billionaire childhood · aired May 13, 2026 · hosted by Sam Parr and Shaan Puri
Why it works
The company capitalizes on acquiring spin-offs from larger conglomerates that are considered distractions, allowing for focused growth and operational efficiency.
Founding story
Founded by Jim Ratcliffe after he and a partner decided to leverage their experience in private equity to buy companies independently, starting with an $80 million acquisition of a BP chemical division.
The playbook
Focus on acquiring undervalued spin-offs, understanding the chemical market deeply, and aiming for significant EBITDA growth.
Also mentioned
Ineos is one of the largest chemical companies in the world and has made significant investments in sports, including ownership stakes in various sports teams.
Why this works now (our analysis)
Most chemical companies ignore the potential of spin-offs, but Ineos thrives by acquiring divisions deemed distractions by larger firms. The company’s initial revenue strategy involved securing contracts through the American Chemistry Council, targeting specific consumer product manufacturers. This focused approach allows Ineos to streamline operations and drive growth. A significant risk lies in the capital intensity of chemical production, which demands substantial upfront investment and poses challenges in securing financing for future expansions.